Abstracts tagged "cerebrovascular disease and systemic lupus erythematosus (SLE)"

Abstract Number: 1082 • 2014 ACR/ARHP Annual Meeting
Risk of Intra Cranial Hemorrhage among Patients with Anti-Phospho-Lipid-Antibody (aPL) syndrome vs Systemic Lupus Erythematosus (SLE) in Stroke Population: A Nationwide Analysis
Tapan Mehta¹, Khushboo Sheth², Ronak Soni³, Sonam Puri² and Kathan Mehta⁴, ¹Neurology, University of Connecticut, Farmington, CT, Farmington, CT, ²Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, ³Internal Medicine, Government Medical College, Surat, India, ⁴Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, Pittsburgh, PA
Background/Purpose Central nervous system involvement is common in Systemic Lupus Erythematosus (SLE) and was first described in 1873. Though ischemic involvement is more common than…
Abstract Number: 658 • 2012 ACR/ARHP Annual Meeting
Up-Regulation of A Disintegrin and Metalloprotease with Thrombospondin Type I Repeats-13 Correlates with Ischemic Cerebrovascular Disease in Systemic Lupus Erythematosus Patients
Consuelo Lopez de Padilla¹, Molly Hein², Cynthia S. Crowson³, Christopher Choo⁴, Abigail B. Green³, Michelle Petri⁵, Hatice Bilgic⁶, Emily Baechler Gillespie⁶ and Ann M. Reed⁷, ¹Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Minnesota Medical School, Minneapolis, MN, ⁷Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: ADAMTS13 (A Disintegrin-like And Metalloprotease with ThromboSpondin type 1 motif) belongs to a recently described group of metalloproteinase enzymes which possess proteoglycanase and anti-angiogenic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].